<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Health Law Counsel, LLC]]></title><description><![CDATA[HEALTH LAW COUNSEL, LLC]]></description><link>https://www.healthlawcounsel.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Tue, 13 Oct 2026 21:34:29 GMT</lastBuildDate><atom:link href="https://www.healthlawcounsel.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Deep Dive: Peptides and Telehealth in 2026 — Looser Access, Tighter Enforcement]]></title><description><![CDATA[Peptides have moved from the fringes of "biohacking" forums into mainstream telehealth menus faster than almost any therapeutic category since GLP-1s. The regulatory picture is contradictory. Federal health leadership has publicly championed broader peptide access, and an FDA advisory committee recently voted to open a lawful compounding pathway for several popular compounds. Over the same period, FDA, the FTC, and state attorneys general have stepped up enforcement against the telehealth...]]></description><link>https://www.healthlawcounsel.com/post/deep-dive-peptides-and-telehealth-in-2026</link><guid isPermaLink="false">6ab44441edc791f96629661a</guid><pubDate>Tue, 13 Oct 2026 15:21:40 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11062b_bee9e23f85bf4220b1054983786981d2~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Andrea Okoro</dc:creator></item></channel></rss>